DOCSLIB.ORG

List of Scheduling Actions, Controlled Substances And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Scheduling Actions, Controlled Substances And U.S. Department of Justice Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section Lists of: Scheduling Actions Controlled Substances Regulated Chemicals August 2021 Foreword The first three sections of this booklet list the names of the substances which are described in the Code of Federal Regulations (CFR) as well as some of those which generate frequent inquiries. The substances are first arranged alphabetically, then by Drug Enforcement Administration (DEA) drug code number, and finally by Controlled Substances Act (21 U.S.C. §801 et seq.) (CSA) schedule. These lists describe the basic or parent chemical and do not describe the salts, isomers, salts of isomers, esters, ethers, and derivatives which may be controlled substances. These are not comprehensive lists so please note that a substance need not be listed as a controlled substance to be treated as a scheduled substance for criminal prosecution. The “Other Names” column, provides some examples of alternate names for certain compounds, and in some instances provides examples of “positional isomers”. If outside parties want to ensure that a compound is not considered a scheduled substance or listed chemical, they should write the DEA, Drug and Chemical Evaluation Section (DRE), Diversion Control Division, 8701 Morrissette Drive, Springfield, Virginia 22152, for an official determination. A substance (not included on these lists) may also be regulated as a controlled substance analogue. A controlled substance analogue is a substance which is intended for human consumption, is structurally substantially similar to a schedule I or schedule II substance, is pharmacologically substantially similar to a schedule I or schedule II substance, or is represented as being similar to a schedule I or schedule II substance and is not an approved medication in the United States. See 21 U.S.C. § 802(32)(A) for the definition of a controlled substance analogue and 21 U.S.C. § 813 for the schedule. The next two sections of this booklet list the Federal Register notices through which the DEA has directed substances to be added, deleted or transferred between schedules of the CSA. The scheduling changes are listed first in alphabetical order by substance and then in chronological order by effective date. With the exception of anabolic steroids, section 812 of the CSA lists only those substances which were controlled in 1970 when the law was enacted. Since then, over 200 substances have been added, removed, or transferred from one schedule to another. The current official list of controlled substances can be found in section 1308 of the most recent issue of Title 21 Code of Federal Regulations Part 1300 to end (21 CFR § 1308) and the final rules which have been published in the Federal Register subsequent to the issuance of the CFR. The CFR and the Federal Register are available on the U.S. Government Printing Office web site at https://www.gpo.gov/fdsys/. This information is accessible, also, on the Diversion Control Division’s website at https://www.deadiversion.usdoj.gov/. The last section of this booklet identifies the “List I” and “List II” chemicals. Certain commercial transactions involving these chemicals are regulated by the CSA. See 21 CFR §§ 1309, 1310 and 1313 for details. These lists are intended as general references and are not comprehensive listings of all controlled substances and regulated chemicals. Drug and Chemical Evaluation Section Diversion Control Division Drug Enforcement Administration Telephone: 202-307-7183 • FAX: 202-353-1263 August 2021 Abbreviations 2C-B = 4-Bromo-2,5-dimethoxyphenethylamine 2C-T-7 = 2,5-Dimethoxy-4(n)-propylthiophenethylamine BZP = N-Benzylpiperazine DMT = Dimethyltryptamine DOM = 4-Methyl-2,5-dimethoxyamphetamine GBL = Gamma butyrolactone GHB = Gamma hydroxybutyric acid, gamma hydroxybutyrate, 4-hydroxybutanoic acid, sodium oxybate LAAM = Levo-alphacetylmethadol LSD = Lysergic acid diethylamide, lysergide MDA = 3,4-Methylenedioxyamphetamine MDE = 3,4-Methylenedioxy-N-ethylamphetamine MDMA = 3,4-Methylenedioxymethamphetamine MPPP = 1-Methyl-4-phenyl-4-propionoxypiperidine P2P = Phenyl-2-propanone, phenylacetone PCC = 1-Piperidinocyclohexanecarbonitrile PCE = N-Ethyl-1-phenylcyclohexylamine PCH = 1-Phenylcyclohexylamine PCP = 1-(1-Phenylcyclohexyl)piperidine, phencyclidine PEPAP = 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine PHP = 1-(1-Phenylcyclohexyl)pyrrolidine SPA = (-)-1-Dimethylamino-1,2-diphenylethane TCP = 1-[1-(2-Thienyl)cyclohexyl]piperidine TCPy = 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine THC = Tetrahydrocannabinols THG = Tetrahydrogestrinone Scheduling Actions Alphabetical Order Scheduling Actions -Alphabetical Order - FINAL ORDER SUBSTANCE PROPOSAL FEDERAL *Scheduled under 21 USC 811(h) PUBLICATION PUBLICATION REGISTER EFFECTIVE CSA **Extension of temporary control DATE DATE CITATION DATE SCHEDULE 11/25/2020 (1-(4-FLUOROBENZYL)-1H-INDOL-3-YL)(2,2,3,3- 04-16-19 84 FR 15505 4/16/2019 I TETRAMETHYLCYCLOPROPYL)METHANONE * (FUB-144) (1-(4-FLUOROBENZYL)-1H-INDOL-3-YL)(2,2,3,3- 03-31-21 86 FR 16669 4/16/2021 I TETRAMETHYLCYCLOPROPYL)METHANONE ** (FUB-144) (1-PENTYL-1H-INDOL-3-YL)(2,2,3,3- 05-16-13 78 FR 28735 5/16/2013 I TETRAMETHYLCYCLOPROPYL)METHANONE (UR-144)* [1-(5-FLUOROPENTYL)-1H-INDAZOL-3- 01-30-15 80 FR 5042 1/30/2015 I YL](NAPHTHALEN-1-YL)METHANONE (THJ-2201)* [1-(5-FLUORO-PENTYL)1H-INDOL-3-YL](2,2,3,3- 05-16-13 78 FR 28735 5/16/2013 I TETRAMETHYLCYCLOPROPYL)METHANONE(5-FLUORO-UR- 144, XLR11)* 1-(1-(1-(4-BROMOPHENYL)ETHYL)PIPERIDIN-4-YL)-1,3- 03-01-21 86 FR 11862 3/1/2021 I DIHYDRO-2H-BENZO[D]IMIDAZOL-2-ONE (BRORPHINE)* 1-(1,3-BENZODIOXOL-5-YL)-2-(ETHYLAMINO)-PENTAN-1- 06-14-21 86 FR 31427 6/14/2021 I ONE (N-ETHYLPENTYLONE, EPHYLONE) 1-(1,3-BENZODIOXOL-5-YL)-2-(ETHYLAMINO)-PENTAN-1- 08-31-18 83 FR 44474 8/31/2018 I ONE (N-ETHYLPENTYLONE, EPHYLONE)* 1-(1,3-BENZODIOXOL-5-YL)-2-(ETHYLAMINO)-PENTAN-1- 08-27-20 85 FR 52915 8/31/2020 I ONE (N-ETHYLPENTYLONE, EPHYLONE)** 1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE (TFMPP) 09-08-03 03-18-04 69 FR 12794 3/19/2004 I --> 0 1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE (TFMPP) * 09-20-02 67 FR 59161 9/20/2002 I 1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE (TFMPP) ** 09-10-03 68 FR 53289 9/20/2003 I 1-(4-CYANOBUTYL)-N-(2-PHENYLPROPAN-2-YL)-1 H- 06-10-21 86 FR 30775 6/10/2021 I INDAZOLE-3-CARBOXAMIDE (4-CN-CUMYL-BUTINACA) 1-(4-CYANOBUTYL)-N-(2-PHENYLPROPAN-2-YL)-1 H- 07-10-18 83 FR 31877 7/10/2018 I INDAZOLE-3-CARBOXAMIDE (4-CN-CUMYL-BUTINACA)* 1-(4-CYANOBUTYL)-N-(2-PHENYLPROPAN-2-YL)-1 H- 07-13-20 85 FR 42296 7/10/2020 I INDAZOLE-3-CARBOXAMIDE (4-CN-CUMYL-BUTINACA)** 1-(5-FLUOROPENTYL)-N-(2-PHENYLPROPAN-2-YL)-1 H- 06-10-21 86 FR 30775 6/10/2021 I PYRROLO[2,3-B]PYRIDINE-3-CARBOXAMIDE(5FCUMYL- P7AICA) 1-(5-FLUOROPENTYL)-N-(2-PHENYLPROPAN-2-YL)-1 H- 07-10-18 83 FR 31877 7/10/2018 I PYRROLO[2,3-B]PYRIDINE-3-CARBOXAMIDE(5FCUMYL- P7AICA)* 1-(5-FLUOROPENTYL)-N-(2-PHENYLPROPAN-2-YL)-1H- 04-16-19 84 FR 15505 4/16/2019 I INDAZOLE-3-CARBOXAMIDE * (5F-CUMYL-PINACA; SGT-25) 1-(5-FLUOROPENTYL)-N-(2-PHENYLPROPAN-2-YL)-1H- 03-31-21 86 FR 16669 4/16/2021 I INDAZOLE-3-CARBOXAMIDE ** (5F-CUMYL-PINACA; SGT- 25) 1-(5-FLUOROPENTYL)-N-(2-PHENYLPROPAN-2-YL)-1H- 07-13-20 85 FR 42296 7/10/2020 I PYRROLO[2,3-B]PYRIDINE-3-CARBOXAMIDE(5FCUMYL- P7AICA)** 1-[1-(2-THIENYL)CYCLOHEXYL]PYRROLIDINE 03-20-89 07-06-89 54 FR 28414 7/6/1989 I Scheduling Actions - Alphabetical Order 27-Aug-21 Page 1 of 15 FINAL ORDER SUBSTANCE PROPOSAL FEDERAL *Scheduled under 21 USC 811(h) PUBLICATION PUBLICATION REGISTER EFFECTIVE CSA **Extension of temporary control DATE DATE CITATION DATE SCHEDULE 19-NOR-4,9(10)-ANDROSTADIENEDIONE (estra-4,9(10)-diene- 04-25-08 12-04-09 74 FR 63603 1/4/2010 III 3,17-dione) 2-(4-BROMO-2,5-DIMETHOXYPHENYL)-N-(2- 11-15-13 78 FR 68716 11/15/2013 I METHOXYBENZYL) ETHANAMINE (25B-NBOMe)* 2-(4-CHLORO-2,5-DIMETHOXYPHENYL)-N-(2- 11-15-13 78 FR 68716 11/15/2013 I METHOXYBENZYL) ETHANAMINE (25C-NBOMe)* 2-(4-IODO-2,5-DIMETHOXYPHENYL)-N-(2-METHOXYBENZYL) 11-15-13 78 FR 68716 11/15/2013 I ETHANAMINE (25I-NBOMe)* 2,5-DIMETHOXY-4-(n)-PROPYLTHIOPHENETHYLAMINE (2C- 09-08-03 03-18-04 69 FR 12794 3/18/2004 I T-7) 2,5-DIMETHOXY-4-(n)-PROPYLTHIOPHENETHYLAMINE (2C- 09-20-02 67 FR 59163 9/20/2002 I T-7) * 2,5-DIMETHOXY-4-(n)-PROPYLTHIOPHENETHYLAMINE (2C- 09-10-03 68 FR 53289 9/20/2003 I T-7) ** 2,5-DIMETHOXY-4-ETHYLAMPHETAMINE (DOET) 10-30-87 01-14-93 58 FR 4316 2/16/1993 I 2,5-DIMETHOXYAMPHETAMINE (DMA) 05-31-73 09-21-73 38 FR 26447 9/21/1973 I 2'-FLUORO ORTHO-FLUOROFENTANYL 04-27-21 86 FR 22113 4/27/2021 I 3,4-DICHLORO-N-[(1- 04-14-16 81 FR 22023 5/15/2016 I DIMETHYLAMINO)CYCLOHEXYLMETHYL]BENZAMIDE) (AH-7921) 3,4-DICHLORO-N-[2-(DIMETHYLAMINO)CYCLOHEXYL]-N- 04-20-18 83 FR 17486 4/20/2018 I METHYLBENZAMIDE (U-47700) 3,4-DICHLORO-N-[2-(DIMETHYLAMINO)CYCLOHEXYL]-N- 11-14-16 81 FR 79389 11/14/2016 I METHYLBENZAMIDE (U-47700)* 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE 10-14-88 04-13-89 54 FR 14797 4/13/1989 I 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE* 10-15-87 52 FR 38225 10/15/1987 I 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE** 10-13-88 53 FR 40061 10/13/1988 I 3,4-METHYLENEDIOXY-N-METHYLCATHINONE 10-21-11 04-12-13 78 FR 21818 4/12/2013 I (METHYLONE) 3,4-METHYLENEDIOXY-N-METHYLCATHINONE 10-21-11 76 FR 65371 10/21/2011 I (METHYLONE)* 3,4-METHYLENEDIOXYPYROVALERONE (MDPV)* 10-21-11 76 FR 65371 10/21/2011 I 3-FLUORO-N-METHYLCATHINONE (3-FMC) 03-04-16 03-01-17 82 FR 12171 3/1/2017 I 3-FLUORO-N-METHYLCATHINONE (3-FMC)* 03-07-14 79 FR 12938 3/7/2014 I 3-FLUORO-N-METHYLCATHINONE (3-FMC)** 03-04-16 81 FR 11429 3/4/2016 I 3-METHYLFENTANYL
Load more

Recommended publications
  • Minnesota Statutes 1979 Supplement
    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
    [Show full text]
  • Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity
    molecules Review Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity Babiker M. El-Haj 1,* and Samrein B.M. Ahmed 2 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, Fufairah 00971, UAE 2 College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah 00971, UAE; [email protected] * Correspondence: [email protected] Received: 6 February 2020; Accepted: 7 April 2020; Published: 22 April 2020 Abstract: Alkyl moieties—open chain or cyclic, linear, or branched—are common in drug molecules. The hydrophobicity of alkyl moieties in drug molecules is modified by metabolic hydroxy functionalization via free-radical intermediates to give primary, secondary, or tertiary alcohols depending on the class of the substrate carbon. The hydroxymethyl groups resulting from the functionalization of methyl groups are mostly oxidized further to carboxyl groups to give carboxy metabolites. As observed from the surveyed cases in this review, hydroxy functionalization leads to loss, attenuation, or retention of pharmacologic activity with respect to the parent drug. On the other hand, carboxy functionalization leads to a loss of activity with the exception of only a few cases in which activity is retained. The exceptions are those groups in which the carboxy functionalization occurs at a position distant from a well-defined primary pharmacophore. Some hydroxy metabolites, which are equiactive with their parent drugs, have been developed into ester prodrugs while carboxy metabolites, which are equiactive to their parent drugs, have been developed into drugs as per se.
    [Show full text]
  • Did Internet-Purchased Diet Pills Cause Serotonin Syndrome?
    Did Internet-purchased diet pills cause serotonin syndrome? Phentermine also may have increased patient’s neuroleptic malignant syndrome risk s. G, age 28, presents to a tertiary® careDowden hospital Health Media with altered mental status. Six weeks ago she Mstarted taking phentermine, 37.5 mg/d, to lose weight. Her body mass indexCopyright is 24 kg/mFor2 (normal personal range), use only and she obtained the stimulant agent via the Internet. Her family reports Ms. G was very busy in the past week, staying up until 2 AM cleaning. They say she also was irritable with her 5-year-old son. Two days ago, Ms. G complained of fatigue and nausea without emesis. She went to bed early and did not awaken the next morning. Her sister found her in bed, minimally re- DIONISI sponsive to verbal stimuli, and brought her to the hospital. Patients have used phentermine as a weight-reducing IMAGES/SANDRA GETTY agent since the FDA approved this amphetamine-like © compound in 1960.1 Phentermine’s mechanism of ac- tion is thought to involve dopaminergic, noradrenergic, Kyoung Bin Im, MD and serotonergic effects.2 Stimulation of norepineph- Chief resident Internal medicine and psychiatry combined residency program rine (NE) release is its most potent effect, followed Departments of internal medicine and psychiatry by NE reuptake inhibition, stimulation of dopamine Jess G. Fiedorowicz, MD (DA) release, DA reuptake inhibition, stimulation of Associate in psychiatry serotonin (5-HT) release, and 5-HT reuptake inhibition Department of psychiatry (weak).3 Roy J. and Lucille A. Carver College of Medicine Because phentermine could in theory cause serotonin 4 University of Iowa syndrome, its use is contraindicated with monoamine Iowa City oxidase inhibitors (MAOIs) and not recommended with selective serotonin reuptake inhibitors (SSRIs).5 One case report describes an interaction between fl uox- etine and phentermine that appears consistent with se- rotonin syndrome.6 We are aware of no case reports of Current Psychiatry serotonin syndrome caused by phentermine alone.
    [Show full text]
  • 2020 Kansas Statutes
    2020 Kansas Statutes 65-4105. Substances included in schedule I. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide) 9821 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide) 9815 (3) Acetylmethadol 9601 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551 (6) Allylprodine 9602 (7) Alphacetylmethadol 9603(except levo-alphacetylmethadol also known as levo- alpha-acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine 9604 (9) Alphamethadol 9605 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) 9814 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide) 9832 (12) Benzethidine 9606 (13) Betacetylmethadol 9607 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide) 9830 (15) Beta-hydroxy-3-methylfentanyl (other
    [Show full text]
  • 2015-02 Toxicology Rapid Testing Panel
    SOUTH CAROLINA LAW ENFORCEMENT DIVISION NIKKI R. HALEY MARK A. KEEL Governor Chief FORENSIC SERVICES LABORATORY CUSTOMER NOTICE 2015-02 REGARDING TOXICOLOGY RAPID TESTING PANEL August 12, 2015 This notice is to inform the Coroners of South Carolina of a new testing panel available through the SLED Toxicology Department. On Monday, August 17th, the Toxicology Department will begin offering both a Rapid Testing Panel in addition to the already available Expanded Testing Panel. This Rapid Testing Panel is to be utilized in cases where the Expanded Testing Panel is not warranted, specifically where a cause of death has already been established. The Rapid Testing Panel will consist of volatiles analysis, to include, ethanol, acetone, isopropanol and methanol, drug screens, and drug confirmation/quantitation of positive screens. The cases assigned to the Rapid Testing Panel will have an expedited turnaround time. Targeted turn around times will be two weeks for negative cases and six weeks or less for positive cases. While every effort will be made to adhere to these time frames, additional time may be required on occasion due to the nature of postmortem samples. Submitters will be notified if there is a problem with a particular sample. Please see attachment regarding specifically which substances are covered by the Rapid Testing Panel and the Expanded Testing Panel. As always, a detailed case history and list of drugs suspected is appreciated. Rapid Panel and Expanded Panel will be choices available in iLAB. Please contact Lt. Dustin Smith (803-896-7385) with additional questions. ALI-359-T An Accredited Law Enforcement Agency P.O.
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • Food and Drug Administration 5630 Fishers Lane, Rm
    Sent via Electronic and U.S. Mail October 13, 2015 James R. Hunter Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2015-N-0045 for International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; Ketamine; Phenazepam; Etizolam; 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine (MT-45); N-(1-Phenethylpiperidin- 4-yl)-N-phenylacetamide (Acetylfentanyl); α-Pyrrolidinovalerophenone (α-PVP); 4- Fluoroamphetamine (4-FA); para-Methyl-4-methylaminorex (4,4’-DMAR); para- Methoxymethylamphetamine (PMMA); 2-(ethylamino)-2-(3-methoxyphenyl)- cyclohexanone (Methoxetamine or MXE); Request for Comments Dear Mr. Hunter: This letter responds to the Food and Drug Administration’s (FDA) request for comments that appeared in the Federal Register on October 5, 2015, concerning International Drug Scheduling. The Association of Public and Land-grant Universities (APLU) represents 237 public research universities, land-grant institutions, state university systems, and affiliated organizations. Many of our member institutions have veterinary and medical schools and nearly all our institutions have researchers and students who conduct biomedical research. On behalf of our institutional membership, APLU appreciates this opportunity to provide the FDA with comments. APLU strongly objects to any attempt to alter the international regulation of ketamine that would result in increased difficulty for biomedical researchers to use this drug for legitimate and appropriate treatments. The United States currently classifies ketamine as a Schedule III drug under the Controlled Substance Act (CSA). As such, strict regulations and safeguards are already in place to prevent its illegal use. As known to FDA, Schedule I drugs are defined as those with no currently acceptable medical use, a lack of accepted safety for use under medical supervision, and a high potential for abuse.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun
    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]